Arcadia Biosciences (RKDA) Asset Writedowns and Impairment (2020 - 2024)

Arcadia Biosciences has reported Asset Writedowns and Impairment for 5 years, with the latest figure at $154000.0 in Q3 2024.

• For the quarter ending Q3 2024, Asset Writedowns and Impairment fell 38.89% year-over-year to $154000.0; the trailing twelve-month figure through Dec 2025 stood at $154000.0 (changed 0.0% YoY), and the FY2024 full-year result was $154000.0, up 670.0% from the prior year.
• Asset Writedowns and Impairment for Q3 2024 stood at $154000.0, up from -$424000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $2.5 million in Q4 2022, with the low at -$424000.0 in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $686352.9 across 5 years, with a median of $252000.0 in 2023.
• The largest YoY upside for Asset Writedowns and Impairment was 1580.0% in 2023 against a maximum downside of 117.18% in 2023.
• Arcadia Biosciences' Asset Writedowns and Impairment stood at $1.2 million in 2020, then jumped by 90.08% to $2.3 million in 2021, then gained by 8.2% to $2.5 million in 2022, then plunged by 117.18% to -$424000.0 in 2023, then soared by 136.32% to $154000.0 in 2024.
• The last three Asset Writedowns and Impairment figures came in at $154000.0 (Q3 2024), -$424000.0 (Q4 2023), and $252000.0 (Q3 2023), per Business Quant data.